智通财经APP获悉，招银国际发布研报称，信达生物(01801)在2024年提前扭亏为盈，全年non-IFRS净利润达到3.32亿元人民币，好过预期，主要来自于期内产品收入强劲增长及一次性授权许可费收入的支持。展望未来可实现持续盈利，维持“买入”评级。该行预期，信达生物旗下mazdutide将获批、持续盈利以及创新在研产品将提供强劲增长动能，相应将今年盈利预测上调89%，目标价从57.67港元上调至61.71港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.